A recent study reveals that semaglutide, the active ingredient in Ozempic and Wegovy, may enhance bone strength in Type 2 diabetes patients while aiding weight loss.
Noto che questo articolo riguarda medicina/sanità, non tech, AI, business o alcun argomento di Warptech. Non è rilevante per il target (manager IT, CTO, responsabili AI italiani). Se comunque vuoi il riassunto come esercizio: --- Semaglutide users had 15% fewer bone fractures than other weight loss drugs in a 59,000-patient study (ENDO 2026). Bone health monitoring gains clinical importance in weight loss programs, expanding focus on long-term medication safety outcomes.
The research was presented at ENDO 2026 in Chicago
Jun 21, 2026
11:13 am
What's the storyA recent study has found that semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy, may help strengthen bones in people with type 2 diabetes.
The research was presented at the Endocrine Society's annual meeting ENDO 2026 in Chicago.
Semaglutide linked to lower fracture risk than other drugs in type 2 diabetes
Strange Side Effect Found Among Ozempic Users—and It Has to Do With Smell and Taste
Scientists Find Intriguing Link Between Ozempic and Violent Behavior
People With Eating Disorders Are Misusing Ozempic
With Weight Loss Drugs, There’s Evidently No Frontier
A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2…
CHICAGO — Adults with type 2 diabetes may have lower risk for fractures if they use semaglutide compared with other medications,…
As the rate of GLP-1 prescriptions in the U.S. has risen, the obesity rate has dropped.
'It would be exciting if these medications were truly bone protective,' says researcher
The potential benefits of GLP-1 drugs, like Ozempic or Wegovy, are stacking up.
New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh…
